Efficacy and safety of long-acting intramuscular testosterone undecanoate in aging men: A randomised controlled study

BJU International

Volumn 111, Issue 7, 2013, Pages 1130-1140

  Tan, Wei Shen ^a,b   Low, Wah Yun ^d   Ng, Chirk Jenn ^d   Tan, Wei Keith ^c   Tong, Seng Fah ^e   Ho, Christopher ^e   Khoo, Ee Ming ^d   Lee, George ^f   Lee, Boon Cheok ^g   Lee, Verna ^h   Tan, Hui Meng ^d,g  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b WHITTINGTON HOSPITAL   (United Kingdom)

^c UNIVERSITY OF BRISTOL   (United Kingdom)

^d UNIVERSITY OF MALAYA   (Malaysia)

^e UNIVERSITI KEBANGSAAN MALAYSIA   (Malaysia)

^f Gleneagles Intan Medical Centre   (Malaysia)

^g Sime Darby Medical Centre   (Malaysia)

^h INTERNATIONAL MEDICAL UNIVERSITY   (Malaysia)

Author keywords

efficacy; hypogonadism; safety; testosterone deficiency; testosterone undecanoate

Indexed keywords

BILIRUBIN; GLUCOSE; HEMOGLOBIN; LONG ACTING DRUG; PLACEBO; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE BINDING GLOBULIN; TESTOSTERONE; TESTOSTERONE UNDECANOATE;

ACNE; ADULT; AGING; ANDROGEN DEFICIENCY; ARTICLE; BACKACHE; BILIRUBIN BLOOD LEVEL; BREAST TENDERNESS; CLINICAL EVALUATION; CONTROLLED STUDY; COUGHING; DIABETIC FOOT; DIGITAL RECTAL EXAMINATION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG FATALITY; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG SAFETY; DRUG TOLERANCE; DYSPNEA; ERECTILE DYSFUNCTION; EYE PAIN; FOOT ULCER; GLUCOSE BLOOD LEVEL; GOUT; HAIR LOSS; HEART INFARCTION; HEMATOCRIT; HEMOGLOBIN BLOOD LEVEL; HOT FLUSH; HUMAN; HYPERPIGMENTATION; HYPERTENSION; INFECTION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; JOINT STIFFNESS; KNEE FRACTURE; LEG PAIN; LETHARGY; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALAYSIA; MALE; MICTURITION DISORDER; NECK PAIN; PAIN; PHYSICAL EXAMINATION; PNEUMONIA; POLYDIPSIA; POLYURIA; PRIORITY JOURNAL; PROSTATE HYPERTROPHY; PSORIASIS; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SHOULDER PAIN; SKIN BRUISING; SLEEP DISORDER; TESTOSTERONE BLOOD LEVEL; THORAX PAIN; THROAT DISEASE; TINNITUS; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION;

ADULT; AGED; AGING; ANDROGENS; BILIRUBIN; BLOOD GLUCOSE; DOUBLE-BLIND METHOD; FASTING; HEMOGLOBINS; HUMANS; INJECTIONS, INTRAMUSCULAR; KALLIKREINS; LIPIDS; MALAYSIA; MALE; MIDDLE AGED; PHYSICAL EXAMINATION; PROSTATE-SPECIFIC ANTIGEN; SEX HORMONE-BINDING GLOBULIN; TESTOSTERONE; TREATMENT OUTCOME;

EID: 84877707872     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/bju.12037     Document Type: Article

References (52)

1. Mulligan T, Frick MF, Zuraw QC, Stemhagen A, McWhirter C,. Prevalence of hypogonadism in males aged at least 45 years: the HIM study. Int J Clin Pract 2006; 60: 762-769
2. Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab 2002; 87: 589-598
3. Van Vliet M, Spruit MA, Verleden G, et al. Hypogonadism, quadriceps weakness, and exercise intolerance in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 172: 1105-1111
4. Handelsman DJ,. Hypothalamic-pituitary gonadal dysfunction in renal failure, dialysis and renal transplantation. Endocr Rev 1985; 6: 151-182
5. Bolona ER, Uraga MV, Haddad RM, et al. Testosterone use in men with sexual dysfunction: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 20-28
6. Srinivas-Shankar U, Roberts SA, Connolly MJ, et al. Effects of testosterone on muscle strength, physical function, body composition, and quality of life in intermediate-frail and frail elderly men: a randomized, double-blind, placebo-controlled study. J Clin Endocrinol Metab 2010; 95: 639-650
7. Behre HM, Kliesch S, Leifke E, Link TM, Nieschlag E,. Long-term effect of testosterone therapy on bone mineral density in hypogonadal men. J Clin Endocrinol Metab 1997; 82: 2386-2390
8. Wang C, Alexander G, Berman N, et al. Testosterone replacement therapy improves mood in hypogonadal men-a clinical research center study. J Clin Endocrinol Metab 1996; 81: 3578-3583
9. Kapoor D, Goodwin E, Channer KS, Jones TH,. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol 2006; 154: 899-906
10. Cunningham GR, Toma SM,. Clinical review: why is androgen replacement in males controversial? J Clin Endocrinol Metab 2011; 96: 38-52
11. Wang C, Nieschlag E, Swerdloff R, et al. Investigation, treatment and monitoring of late-onset hypogonadism in males: ISA, ISSAM, EAU, EAA and ASA recommendations. Eur J Endocrinol 2008; 159: 507-514
12. Bhasin S, Woodhouse L, Casaburi R, et al. Older men are as responsive as young men to the anabolic effects of graded doses of testosterone on the skeletal muscle. J Clin Endocrinol Metab 2005; 90: 678-688
13. Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in men with androgen deficiency syndromes: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2010; 95: 2536-2559
14. Murphy M, Carmichael AJ,. Transdermal drug delivery systems and skin sensitivity reactions. Incidence and management. Am J Clin Dermatol 2000; 1: 361-368
15. de Ronde W,. Hyperandrogenism after transfer of topical testosterone gel: case report and review of published and unpublished studies. Hum Reprod 2009; 24: 425-428
16. Kelleher S, Turner L, Howe C, Conway AJ, Handelsman DJ,. Extrusion of testosterone pellets: a randomized controlled clinical study. Clin Endocrinol (Oxf) 1999; 51: 469-471
17. Moon du G, Park MG, Lee SW, et al. The efficacy and safety of testosterone undecanoate (Nebido((R))) in testosterone deficiency syndrome in Korean: a multicenter prospective study. J Sex Med 2010; 7: 2253-2260
18. Tong SF, Ng CJ, Lee BC, et al. Effect of long-acting testosterone undecanoate treatment on quality of life in men with testosterone deficiency syndrome: a double blind randomised controlled trial. Asian J Androl 2012; 14: 604-611
19. Ho CC, Tong SF, Low WY, et al. A randomized, double-blind, placebo-controlled trial on the effect of long-acting testosterone treatment as assessed by the Aging Male Symptoms scale. BJU Int 2012; 110: 260-265
20. Tan WS, Ng CJ, Khoo EM, Low WY, Tan HM,. The triad of erectile dysfunction, testosterone deficiency syndrome and metabolic syndrome: findings from a multi-ethnic Asian men study (The Subang Men's Health Study). Aging Male 2011; 14: 231-236
21. Bhasin S, Zhang A, Coviello A, et al. The impact of assay quality and reference ranges on clinical decision making in the diagnosis of androgen disorders. Steroids 2008; 73: 1311-1317
22. Permpongkosol S, Tantirangsee N, Ratana-olarn K,. Treatment of 161 men with symptomatic late onset hypogonadism with long-acting parenteral testosterone undecanoate: effects on body composition, lipids, and psychosexual complaints. J Sex Med 2010; 7: 3765-3774
23. Minnemann T, Schubert M, Hubler D, et al. A four-year efficacy and safety study of the long-acting parenteral testosterone undecanoate. Aging Male 2007; 10: 155-158
24. Yeap BB, Chubb SA, Hyde Z, et al. Lower serum testosterone is independently associated with insulin resistance in non-diabetic older men: the Health In Men Study. Eur J Endocrinol 2009; 161: 591-598
25. Selvin E, Feinleib M, Zhang L, et al. Androgens and diabetes in men: results from the Third National Health and Nutrition Examination Survey (NHANES III). Diabetes Care 2007; 30: 234-238
26. Simon D, Charles MA, Lahlou N, et al. Androgen therapy improves insulin sensitivity and decreases leptin level in healthy adult men with low plasma total testosterone: a 3-month randomized placebo-controlled trial. Diabetes Care 2001; 24: 2149-2151
27. Pasquali R, Macor C, Vicennati V, et al. Effects of acute hyperinsulinemia on testosterone serum concentrations in adult obese and normal-weight men. Metabolism 1997; 46: 526-529
28. Svartberg J, von Muhlen D, Sundsfjord J, Jorde R,. Waist circumference and testosterone levels in community dwelling men. The Tromso study. Eur J Epidemiol 2004; 19: 657-663
29. Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med 2010; 7: 3495-3503
30. Kalinchenko SY, Tishova YA, Mskhalaya GJ, Gooren LJ, Giltay EJ, Saad F,. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double-blinded placebo-controlled Moscow study. Clin Endocrinol (Oxf) 2010; 73: 602-612
31. Sih R, Morley JE, Kaiser FE, Perry HM 3rd, Patrick P, Ross C,. Testosterone replacement in older hypogonadal men: a 12-month randomized controlled trial. J Clin Endocrinol Metab 1997; 82: 1661-1667
32. Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle-aged men: a meta-analysis. Clin Endocrinol (Oxf) 2005; 63: 280-293
33. Basaria S, Coviello AD, Travison TG, et al. Adverse events associated with testosterone administration. N Engl J Med 2010; 363: 109-122
34. Zitzmann M, Mattern A, Hanisch J, Gooren L, Jones H, Maggi M,. IPASS: a study on the tolerability and effectiveness of injectable testosterone undecanoate for the treatment of male hypogonadism in a worldwide sample of 1,438 men. J Sex Med 2013; 10: 579-588
35. Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care 2011; 34: 828-837
36. Fernandez-Balsells MM, Murad MH, Lane M, et al. Clinical review 1: adverse effects of testosterone therapy in adult men: a systematic review and meta-analysis. J Clin Endocrinol Metab 2010; 95: 2560-2575
37. Soe KL, Soe M, Gluud C,. Liver pathology associated with the use of anabolic-androgenic steroids. Liver 1992; 12: 73-79
38. Rhoden EL, Morgentaler A,. Risks of testosterone-replacement therapy and recommendations for monitoring. N Engl J Med 2004; 350: 482-492
39. Navarro JF,. In the erythropoietin era, can we forget alternative or adjunctive therapies for renal anaemia management? The androgen example. Nephrol Dial Transplant 2003; 18: 2222-2226
40. Erikssen G, Thaulow E, Sandvik L, Stormorken H, Erikssen J,. Haematocrit: a predictor of cardiovascular mortality? Journal of Internal Medicine 1993; 234: 493-499
41. Lowe GD, Lee AJ, Rumley A, Price JF, Fowkes FG,. Blood viscosity and risk of cardiovascular events: the Edinburgh Artery Study. Br J Haematol 1997; 96: 168-173
42. Morgentaler A,. Words of wisdom. Re: adverse events associated with testosterone administration. Eur Urol 2011; 59: 465
43. Haddad RM, Kennedy CC, Caples SM, et al. Testosterone and cardiovascular risk in men: a systematic review and meta-analysis of randomized placebo-controlled trials. Mayo Clin Proc 2007; 82: 29-39
44. Roddam AW, Allen NE, Appleby P, Key TJ,. Endogenous sex hormones and prostate cancer: a collaborative analysis of 18 prospective studies. Journal of the National Cancer Institute 2008; 100: 170-183
45. Marks LS, Mazer NA, Mostaghel E, et al. Effect of testosterone replacement therapy on prostate tissue in men with late-onset hypogonadism: a randomized controlled trial. JAMA 2006; 296: 2351-2361
46. Kaufman JM, Miller MG, Garwin JL, Fitzpatrick S, McWhirter C, Brennan JJ,. Efficacy and safety study of 1.62% testosterone gel for the treatment of hypogonadal men. J Sex Med 2011; 8: 2079-2089
47. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR,. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003; 24: 299-311
48. Behre HM, Bohmeyer J, Nieschlag E,. Prostate volume in testosterone-treated and untreated hypogonadal men in comparison to age-matched normal controls. Clin Endocrinol (Oxf) 1994; 40: 341-349
49. Shigehara K, Sugimoto K, Konaka H, et al. Androgen replacement therapy contributes to improving lower urinary tract symptoms in patients with hypogonadism and benign prostate hypertrophy: a randomised controlled study. Aging Male 2011; 14: 53-58
50. Kalinchenko SY, Kozlov GI, Gontcharov NP, Katsiya GV,. Oral testosterone undecanoate reverses erectile dysfunction associated with diabetes mellitus in patients failing on sildenafil citrate therapy alone. Aging Male 2003; 6: 94-99
51. Shabsigh R,. Testosterone therapy in erectile dysfunction and hypogonadism. J Sex Med 2005; 2: 785-792
52. Minnemann T, Schubert M, Freude S, et al. Comparison of a new long-acting testosterone undecanoate formulation vs testosterone enanthate for intramuscular androgen therapy in male hypogonadism. J Endocrinol Invest 2008; 31: 718-723